
The claims defining the invention are as follows:

1. A compound of Formula (I-G-1):



;

wherein:
R^3 is hydrogen, $-OCH_3$ or -NH-CH(=O);
each R^{5A} and R^{5B} respectively selected from:

(b) R^{5A} and R^{5B} are each independently hydrogen, or lower alkyl;
provided that:
R^{5A} and R^{5B} are not hydrogen at the same time,

(b) R^{5A} and R^{5B} are taken together with the neighboring atom to form optionally substituted carbocycle or a optionally substituted heterocyclic group, or

c) R^{5A} and R^{5B} are taken together to form optionally substituted methylidene;

L is $-CH_2-$, -CH=CH-, $-CH_2-CH=CH-$, $-CH=CH-CH_2-$, -S-, $-CH_2-S-$, $-CH=CH-S-$ or $-CH=CH-CH_2-S-$;

E is an optionally substituted divalent group having at least one quaternary ammonium ion;


X is N, C(-H) or C(-Cl);

R^7 and R^8 are each independently hydrogen, halogen, hydroxyl, carboxyl, optionally substituted lower alkyl, an optionally substituted carbocyclic group, or an optionally substituted heterocyclic group, or
R^7 and R^8 may be taken together with a neighboring atom to form an optionally substituted carbocyclic group or an optionally substituted heterocyclic group;

Q is a single bond, an optionally substituted carbocyclic group or an optionally substituted heterocyclic group;

m is an integer from 0 to 3;

R^{10} is hydrogen or a group represented by the formula (I-B):



(I-B)

;

provided that:

when R^{10} is hydrogen, E is an optionally substituted divalent cyclic group having at least one quarternary ammonium ion and at least two hydroxyl groups which bind respectively to carbon atoms each adjacently located on the divalent cyclic group;

wherein:

ring A is a benzene ring, monocyclic heterocycle or fused heterocycle;

n is an integer from 0 to 2;

each R^4 independently is hydrogen, halogen, oxo, -OH, -CN, $-NO_2$, $-O-C(=O)-R^9$, $-C(=O)-R^9$, $-C(=O)-OH$, $-C(=O)-OR^9$, $-OR^9$', $-NR^9R^9$, $-SO_2R^9$, $-SR^9$, $-NR^9-C(=O)-R^9$, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;

provided that:

two hydroxyl groups on ring A bind respectively to carbon atoms each adjacently locates;

wherein:

each R^9 is independently lower alkyl or halo(lower)alkyl;

G is a single bond, optionally substituted lower alkylene, optionally substituted alkenylene or optionally substituted alkynylene;

B is non-existent, a single bond or a 5- or 6-membered heterocyclic group containing at least 1-3 nitrogen atoms;

D is non-existent, a single bond, -C(=O)-,

-O-C(=O)-, -C(=O)-O-, $-NR^6-$, $-NR^6-C(=O)-$, $-C(=O)-NR^6-$, $-C(=O)-C(=O)-$, $-NR^6-C(=O)-NR^6-$, $-C(=O)-C(=O)-NR^6-$, $-C(=O)-NR^6-C(=O)-$, $-NR^6-C(=O)-C(=O)-$, $-NR^6-NR^6-C(=O)-$, $-C(=O)-NR^6-NR^6-$, -N=N-C(=O)-, -C(=O)-N=N-, $-C=N-NR^6-C(=O)-$, -C=N-C(=O)-, -N=C-C(=O)-, $-C=N-C(=O)-NR^6-$, $-NR^6-C(=O)-C(=N-OR^6)-$, $-C(=N-OR^6)-C(=O)-NR^6-$, $-NR^6-C(=N-OR^6)-$, $-C(=N-OR^6)-NR^6-$, $-C(=O)-C(=N-OR^6)-$, $-C(=N-OR^6)-C(=O)-$, -O-, -S-, -S(=O)-, $-S(=O)_2-NR^6-$, $-NR^6-S(=O)_2-$, $-NR^6-CH_2-$, $-CH_2-NR^6-$ or $-S(=O)_2-$;


wherein:

each R^6 is independently hydrogen or optionally substituted lower alkyl; or

a pharmaceutically acceptable salt thereof.

2. The compound of Formula (I-G-1), or a pharmaceutically acceptable salt thereof according to claim 1, wherein R^{5A} is hydrogen and R^{5B} is lower alkyl.


3. The compound of Formula (I-G-1) or a pharmaceutically acceptable salt thereof according to either claim 1 or claim 2, wherein R^{10} is a group represented by the formula (I-B):



(I-B)

and G, B, D, R^4 and n are as defined in claim 1, and ring A is a benzene ring or monocyclic heterocycle.

4. The compound of Formula (I-G-1) or a pharmaceutically acceptable salt thereof according to claim 1, wherein:
R^{5A} is hydrogen and R^{5B} is lower alkyl;
R^{10} is a group represented by the formula (I-B);





(I-B)


wherein:


G, B, D, A, R^4 and n are as defined in claim 1.


5. The compound of Formula (I-G-1) or a pharmaceutically acceptable salt thereof according to claim 1 or claim 2 wherein:
X is C(-H), C(-Cl) or N;
each R^7 and R^8 is independently hydrogen or lower alkyl;
R3 is hydrogen;
m is 0 or 1;
Q is a single bond;
L is -CH2-;
E is a group selected from the following formulae;



(2)



(5)


(7)



(10)


(11)






(26)


(77)

wherein, Rx is lower alkyl,
p is an integer from 1 to 3;
G is a single bond or lower alkylene;
B is non-existent or a single bond;
D is non-existent, a single bond, -C(=O)-, -C(=O)-C(=O)-, $-NR^6-C(=O)-C(=O)-$, $-NR^6-C(=O)-$ or $-NH-C(=O)-C(=N-OR^{6a})$;
R^6 is hydrogen or lower alkyl;
R^{6a} is hydrogen, methyl, carboxymethyl, or 2-carboxypropane-2-yl;
the formula (1-B-2);


(I-B-2)


is a group selected from the following formulae;

wherein:


each R^{4a}, R^{4b} and R^{4c} is independently hydrogen, halogen or lower alkyl; R^{4d} is hydrogen, lower alkyl or lower cycloalkyl.


6. The compound of Formula (I-G-1) or a pharmaceutically acceptable salt thereof according to either claim 1 or claim 2, wherein the formula (I-C-1):




(I-C-1)

is a group selected from the following formulae:









wherein:

R^6 is hydrogen, methyl, ethyl, tert-butyl, carboxymethyl, 2-carboxypropan-2-yl or 1-carboxyethyl; and


wherein the wavy line means that the bond is in cis or trans configuration, or a mixture thereof.

7. The compound of Formula (I-G-1) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein E is a group selected from the following formulae which are optionally substituted on the ring:



(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)




(21)




(22)




(23)




(24)




(25)




(26)




(27)




(28)




(29)




(30)




(31)




(32)




(33)




(34)




(35)




(36)




(37)




(38)




(39)




(40)




(41)




(42)




(43)




(44)




(45)




(46)




(47)




(48)




(49)




(50)




(51)




(52)




(53)




(54)




(55)




(56)




(57)




(58)




(59)




(60)




(61)




(62)




(63)




(64)




(65)




(66)




(67)




(68)




(69)




(70)




(71)




(72)




(73)




(74)



(75)



(76)



(77)


wherein the bond to the quaternary nitrogen atom binds to L, and the other bond binds to R^{10};

p is an integer from 1 to 3;

n is an integer of 1 or 2;

R^X is optionally substituted lower alkyl.


8. A compound which is:



; or

a pharmaceutically acceptable salt thereof.

9. A compound which is:



I-100

10. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 and at least one or more pharmaceutically acceptable excipients.

11. Use of compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 in preparation of a medicament for use in antimicrobial therapy.

12. Use of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 in preparation of a medicament for use in therapy against infection by Gram-Negative bacteria.

13. Use of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 in preparation of a medicament for use in therapy against infection by beta-lactamase producing Gram-Negative bacteria.

14. Use of a compound or a pharmaceutically acceptable salt thereof according to any one of the claims 1 to 9 in preparation of a medicament for use in therapy against infection by:

- Gram-Negative bacteria selected from enterobacteria;
- Gram negative bacteria colonized in respiratory system selected from Haemophilus and Moraxella;
- Gram negative bacteria of glucose non fermentation selected from Pseudomonas aeruginosa, Pseudomonas other than P. aeruginosa, Stenotrophomonas, Burkholderia and

Acinetobacter;

- Gram negative multidrug-resistant bacteria selected from Class B type metallo-beta-lactamase producing Gram negative bacteria; and
- extended-spectrum beta-lactamase (ESBL) producing bacteria.

15. Use of a compound or a pharmaceutically acceptable salt thereof according to any one of the claims 1 to 9 in preparation of a medicament for use in therapy against infection by Gram positive bacteria selected from methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP).

16. Use of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 in preparation of a medicament for use in treating a bacterial infection which is an airway infection, urinary system infection, resipiratory system infection, sepsis infection, nephritis, cholecystitis, oral cavity infection, endocarditis, pneumonia, bone marrow membrane myelitis, otitis media, enteritis, empyema, wound infection or an opportunistic infection.